Contrary to expectations, professions that are typically slow to adopt new technology (medicine, law) are showing massive enthusiasm for AI. This is because it directly addresses their core need to reason with and manage large volumes of unstructured data, improving their daily work.

The most effective AI strategy focuses on 'micro workflows'—small, discrete tasks like summarizing patient data. By optimizing these countless small steps, AI can make decision-makers 'a hundred-fold more productive,' delivering massive cumulative value without relying on a single, high-risk autonomous solution.

The most significant opportunity for AI in healthcare lies not in optimizing existing software, but in automating 'net new' areas that once required human judgment. Functions like patient engagement, scheduling, and symptom triage are seeing explosive growth as AI steps into roles previously held only by staff.

Software engineering is a prime target for AI because code provides instant feedback (it works or it doesn't). In contrast, fields like medicine have slow, expensive feedback loops (e.g., clinical trials), which throttles the pace of AI-driven iteration and adoption. This heuristic predicts where AI will make the fastest inroads.

While AI holds long-term promise for molecule discovery, its most significant near-term impact in biotech is operational. The key benefits today are faster clinical trial recruitment and more efficient regulatory submissions. The revolutionary science of AI-driven drug design is still in its earliest stages.

While AI is a universal trend, its application is highly contextual. In drug discovery, it's used for complex, high-science tasks like protein folding. In the CDMO space, its value lies in streamlining less glamorous but critical functions like communication, paperwork, and process optimization.

While AI has vast potential, its most immediate and successful entry point is automating prior authorizations. This administrative bottleneck is considered an 'easy win' because it's non-patient-facing, has a clear ROI, and sits at the front of treatment, leading to natural and rapid adoption.

Unlike the top-down, regulated rollout of EHRs, the rapid uptake of AI in healthcare is an organic, bottom-up movement. It's driven by frontline workers like pharmacists who face critical staffing shortages and need tools to manage overwhelming workloads, pulling technology in out of necessity.

While AI-driven drug discovery is the ultimate goal, Titus argues its most practical value is in improving business efficiency. This includes automating tasks like literature reviews, paper drafting, and procurement, freeing up scientists' time for high-value work like experimental design and interpretation.